Combining stem cell transplantation with CD19-CART for treating high-risk leukemia in adults

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study evaluates the effectiveness and safety of autologous hematopoietic stem cell transplantation combined with CD19-CART therapy in adults diagnosed with high-risk acute lymphoblastic leukemia (ALL). Participants who have achieved complete remission after induction chemotherapy and have successfully prepared autologous CD19-CAR-T will receive this combined treatment. The study aims to observe both the efficacy and potential side effects of this innovative approach in managing ALL.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Adult patients with high-risk acute B-lymphoblastic leukemia
* Complete remission was achieved after induction chemotherapy, and autologous CD19-CAR-T was successfully prepared
* Eligible for autologous hematopoietic stem cell transplantation
* No major organ dysfunction

Exclusion Criteria:

* Combined with malignant tumors of other organs
* With a serious infection that is not under control
* Syphilis, AIDS, hepatitis B, hepatitis C, any one of them positive
* Patients who have had an allergic reaction to the drugs used in this study or similar drugs
* Other patients deemed unsuitable for inclusion by the investigators

Where it's running

• NO.288 Nanjing Road，Heping District，Tianjin, Tianjin,
  Tianjin, Tianjin Municipality, China Recruiting

Study contacts

• Study coordinator: erlie EL Jiang
• Email: jiangerlie@ihcams.ac.cn
• Phone: +86-15122538106

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Isometric wall squat exercise to lower blood pressure in adults with hypertension

  We’re testing whether doing isometric wall squats at home for 12 weeks can help lower 24-hour blood pressure in adults with essential hypertension.

  Recruiting Korea University Guro Hospital · Seoul, Seoul · NCT07868822

• CAYA cancer patients in LMICs: a forward-looking observation of care and outcomes

  This study follows children, teens, and young adults with cancer in low- and middle-income countries to see how routine care affects treatment, access, and outcomes over time.

  Recruiting Resonance, Inc. · Yerevan and 5 other locations · NCT07632014

• Ring-style blood pressure bracelet test compared with 24-hour monitoring in people with HFrEF

  A ring-type blood pressure device is being tested to see if its 24-hour readings match those from standard ambulatory monitoring in adults with heart failure and reduced ejection fraction.

  Recruiting Keimyung University Dongsan Medical Center · Daegu · NCT07626879

• First-in-human testing of 4A10 for relapsed or hard-to-treat ALL and lymphoblastic lymphoma

  This early-stage trial tests a new antibody therapy called 4A10 in patients with relapsed or hard-to-treat acute lymphoblastic leukemia or lymphoblastic lymphoma to see if it is safe and how the body handles it.

  Recruiting at 5 sites Phase 1 Allterum Therapeutics, Inc · Aurora, Colorado and 6 other locations · NCT07586618

• TSLPR-CART therapy for CRLF2-R/TSLPR–expressing B-ALL in adults

  This study tests a CAR T-cell treatment called TSLPR-CART in adults whose B-ALL cells overexpress TSLPR and have not responded to standard therapy.

  Recruiting Phase 1 National Institutes of Health Clinical Center (CC) · Bethesda, Maryland · NCT07572136

• Plasma cell-free DNA in children with ALL to help monitor disease

  This study tests whether measuring tumor DNA in blood can help monitor acute lymphoblastic leukemia in kids without needing frequent bone-marrow tests.

  Recruiting at 2 sites Assistance Publique - Hôpitaux de Paris · Paris and 1 other locations · NCT07483476

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.